Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 28;5(7):710-23.
doi: 10.7150/thno.11387. eCollection 2015.

Graphene as cancer theranostic tool: progress and future challenges

Affiliations
Review

Graphene as cancer theranostic tool: progress and future challenges

Marco Orecchioni et al. Theranostics. .

Abstract

Nowadays cancer remains one of the main causes of death in the world. Current diagnostic techniques need to be improved to provide earlier diagnosis and treatment. Traditional therapy approaches to cancer are limited by lack of specificity and systemic toxicity. In this scenario nanomaterials could be good allies to give more specific cancer treatment effectively reducing undesired side effects and giving at the same time accurate diagnosis and successful therapy. In this context, thanks to its unique physical and chemical properties, graphene, graphene oxide (GO) and reduced graphene (rGO) have recently attracted tremendous interest in biomedicine including cancer therapy. Herein we analyzed all studies presented in literature related to cancer fight using graphene and graphene-based conjugates. In this context, we aimed at the full picture of the state of the art providing new inputs for future strategies in the cancer theranostic by using of graphene. We found an impressive increasing interest in the material for cancer therapy and/or diagnosis. The majority of the works (73%) have been carried out on drug and gene delivery applications, following by photothermal therapy (32%), imaging (31%) and photodynamic therapy (10%). A 27% of the studies focused on theranostic applications. Part of the works here discussed contribute to the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities. We found that the use of graphene in cancer theranostics is still in an early but rapidly growing stage of investigation. Any technology based on nanomaterials can significantly enhance their possibility to became the real revolution in medicine if combines diagnosis and therapy at the same time. We performed a comprehensive summary of the latest progress of graphene cancer fight and highlighted the future challenges and the innovative possible theranostic applications.

Keywords: cancer; carbon materials; graphene; nanomedicine; theranostics; therapy.; tumor.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Percentage of publications of graphene in cancer fight (2008 to November 2014).
Figure 2
Figure 2
Status of Graphene publications in the last 7 years for cancer fight. A) Percentage of manuscripts based on the applications against cancer. B) Venn diagram based on the main applications (Drug Delivery, Phototermal therapy, Photodynamic therapy, Imaging). In the red round the theranostic studies.
Figure 3
Figure 3
Overview on different type of cancer treated with graphene. Manuscripts percentages per type of studied cancer.
Figure 4
Figure 4
Analysis of the amount of publications of graphene in drug delivery applications based on type of loaded drugs.
Figure 5
Figure 5
Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer.

References

    1. Lopez-Gomez M, Malmierca E, de Gorgolas M, Casado E. Cancer in developing countries: the next most preventable pandemic. The global problem of cancer. Critical reviews in oncology/hematology. 2013;88:117–22. doi:10.1016/j.critrevonc.2013.03.011. - PubMed
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69–90. doi:10.3322/caac.20107. - PubMed
    1. Madeddu R, Solinas G, Forte G, Bocca B, Asara Y, Tolu P. et al. Diet and nutrients are contributing factors that influence blood cadmium levels. Nutrition research. 2011;31:691–7. doi:10.1016/j.nutres.2011.09.003. - PubMed
    1. Fernandez-Fernandez A, Manchanda R, McGoron AJ. Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms. Applied biochemistry and biotechnology. 2011;165:1628–51. doi:10.1007/s12010-011-9383-z. - PMC - PubMed
    1. Shanmugam V, Selvakumar S, Yeh CS. Near-infrared light-responsive nanomaterials in cancer therapeutics. Chemical Society reviews. 2014;43:6254–87. doi:10.1039/c4cs00011k. - PubMed

Publication types

LinkOut - more resources